StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3025% above fair value
$232.23−4.75 (-2.00%)

Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –

Danaher Diagnostics by Quarter

Diagnostics — Price Realization (reflecting China VBP centralized procurement) (%)

QuarterlyAnnual

Danaher Diagnostics: -1.0% in Q3 2026, up 0.5 pts from a year earlier.

Latest, Q3 2026
-1.0%
Period ended Sep 30, 2026
Change on a year earlier
+0.5 pts
-1.5% in Q3 2025
History
16 quarters
Since Q1 2021
Sources
16
Documents cited below

Where the Q3 2026 figure comes from

“Price decreases in the segment of 1.0% and 1.5%, respectively, in the three and nine-month periods ended September 25, 2026 were primarily attributable to the impact of China’s volume-based procurement program and reimbursement changes, as well as the impact of sales promotions and are reflected as a component of core sales above.”

Source: Danaher SEC 10-Q (2026Q3, filed 2026-10-21) ↗

Reported for Q1, Q2, Q3 (10-Q) and full year (10-K), with no standalone Q4 reported. Directly reflects price reductions from the volume-based procurement (VBP) program and medical insurance reimbursement reforms in China (-2.0% Q1, -1.5% Q2, -1.0% Q3 2026).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDiagnostics — Price Realization (reflecting China VBP centralized procurement) (%)Year on yearSource
Q3 2026Sep 30, 2026-1.0%+0.5 ptsDanaher SEC 10-Q (2026Q3, filed 2026-10-21) ↗
Q2 2026Jun 30, 2026-1.5%-0.5 ptsDanaher SEC 10-Q (2026Q2, filed 2026-07-21) ↗
Q1 2026Mar 31, 2026-2.0%-1.5 ptsDanaher SEC 10-Q (2026Q1, filed 2026-04-21) ↗
Q3 2025Sep 30, 2025-1.5%–Danaher SEC 10-Q (2025Q3, filed 2025-10-21) ↗
Q2 2025Jun 30, 2025-1.0%–Danaher SEC 10-Q (2025Q2, filed 2025-07-22) ↗
Q1 2025Mar 31, 2025-0.5%-1.0 ptsDanaher SEC 10-Q (2025Q1, filed 2025-04-22) ↗
Q1 2024Mar 31, 20240.5%-0.5 ptsDanaher SEC 10-Q (2024Q1, filed 2024-04-23) ↗
Q3 2023Sep 30, 20231.0%0.0 ptsDanaher SEC 10-Q (2023Q3, filed 2023-10-24) ↗
Q2 2023Jun 30, 20231.0%-0.5 ptsDanaher SEC 10-Q (2023Q2, filed 2023-07-25) ↗
Q1 2023Mar 31, 20231.0%+0.5 ptsDanaher SEC 10-Q (2023Q1, filed 2023-04-25) ↗
Q3 2022Sep 30, 20221.0%+0.5 ptsDanaher SEC 10-Q (2022Q3, filed 2022-10-20) ↗
Q2 2022Jun 30, 20221.5%+1.0 ptsDanaher SEC 10-Q (2022Q2, filed 2022-07-21) ↗
Q1 2022Mar 31, 20220.5%0.0 ptsDanaher SEC 10-Q (2022Q1, filed 2022-04-21) ↗
Q3 2021Sep 30, 20210.5%–Danaher SEC 10-Q (2021Q3, filed 2021-10-21) ↗
Q2 2021Jun 30, 20210.5%–Danaher SEC 10-Q (2021Q2, filed 2021-07-22) ↗
Q1 2021Mar 31, 20210.5%–Danaher SEC 10-Q (2021Q1, filed 2021-04-22) ↗

Cite this data

StockData. (2026). Danaher Diagnostics (%), quarterly Q1 2021–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/mda-price-impact-diag

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.